Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887045 | 0.93 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAMAPK1NAMPTNPC1 | |
| SCHEMBL5886766 | 0.93 | NPC1 (0.45) | SMN1; SMN2LMNANAMPTNPC1GFER | |
| SCHEMBL5887334 | 0.93 | ALDH1A1 (0.44) | ACHEBACE1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL5887467 | 0.92 | KDM4E (0.46) | SMN1; SMN2LMNAMAPK1NPC1GFER | |
| SCHEMBL5887021 | 0.92 | SMN1; SMN2 (0.45) | SMN1; SMN2NAMPTNPC1GFERALDH1A1 | |
| SCHEMBL5886825 | 0.91 | NPC1 (0.45) | SMN1; SMN2LMNAMAPK1NAMPTNPC1 | |
| SCHEMBL5887183 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAMAPK1NAMPTNPC1 | |
| SCHEMBL5887201 | 0.90 | KDM4E (0.47) | ACHESMN1; SMN2LMNAMAPK1NPC1 | |
| SCHEMBL5886974 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAMAPK1NAMPTHTT | |
| SCHEMBL5887375 | 0.90 | NPC1 (0.44) | SMN1; SMN2LMNANAMPTNPC1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | ACHE 3502/4885BACE1 3432/4885SMN1; SMN2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.